share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Smither John W

Arcutis Biotherapeutics | 4：持股变动声明-高管 Smither John W

SEC announcement ·  02/15 18:28
Moomoo AI 已提取核心信息
Arcutis Biotherapeutics, Inc. (ARQT) reported that its Chief Financial Officer, John W Smither, acquired a total of 11,365 shares of common stock on February 13, 2024. The transactions were classified as 'A' for acquisition under the transaction code, indicating they were likely grants or awards. Following these acquisitions, Smither directly holds 11,365 shares. Additionally, it was disclosed that Smither indirectly holds 141,392 shares of Arcutis Biotherapeutics common stock through a trust.
Arcutis Biotherapeutics, Inc. (ARQT) reported that its Chief Financial Officer, John W Smither, acquired a total of 11,365 shares of common stock on February 13, 2024. The transactions were classified as 'A' for acquisition under the transaction code, indicating they were likely grants or awards. Following these acquisitions, Smither directly holds 11,365 shares. Additionally, it was disclosed that Smither indirectly holds 141,392 shares of Arcutis Biotherapeutics common stock through a trust.
Arcutis Biotherapeutics, Inc.（ARQT）报告称，其首席财务官约翰·史密瑟于2024年2月13日共收购了11,365股普通股。根据交易代码，这些交易被归类为收购交易的 “A”，这表明它们很可能是补助金或奖励。在这些收购之后，史密瑟直接持有11,365股股票。此外，据透露，史密瑟通过信托间接持有141,392股Arcutis Biotherapeutics普通股。
Arcutis Biotherapeutics, Inc.（ARQT）报告称，其首席财务官约翰·史密瑟于2024年2月13日共收购了11,365股普通股。根据交易代码，这些交易被归类为收购交易的 “A”，这表明它们很可能是补助金或奖励。在这些收购之后，史密瑟直接持有11,365股股票。此外，据透露，史密瑟通过信托间接持有141,392股Arcutis Biotherapeutics普通股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息